CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

NCT01746992 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

ALK-negative Anaplastic Large Cell Lymphoma
Peripherial T Cell Lymphoma,Not Otherwise Specified
Angioimmunoblastic T Cell Lymphoma
Enteropathy Associated T Cell Lymphoma
Hepatosplenic T Cell Lymphoma
Subcutaneous Panniculitis Like T Cell Lymphoma

Interventions

DRUG: Cyclophosphamide 750mg/m2
DRUG: Vincristine 1.4mg/m2
DRUG: Doxorubicin 50mg/m2
DRUG: prednisone 60mg/m2
DRUG: ifosfamide 2000mg/m2
DRUG: pirarubicin 50mg/m2
DRUG: pirarubicin 25mg/m2
DRUG: Etoposide phosphate 100mg/m2
DRUG: methotrexate 1500mg/m2

Sponsor

Ruijin Hospital